I am going with original estimates.
Analysts have been wrong about HZNP mostly.
If HZNP misses, it will be the first quarter after years of beating. AAPL,GILD and TWTR missed too. Analysts say next quarter will be worse than Q1.
The stock can go either way. If HZNP reports anything above $.50/shr then it will be a good sign but anything less than $.50/shr may disappoint investors.
Not only Zurampic is targeting 2 millions people but also different variation and combination with other drugs will be developed which there will be no need for krystexxa.
Name is Zurampic, developed by AstraZeneca. It is used for uncontrolled gout.
This will kill krystexxa. TW waisted $510m and favored his old friends.
Now, which law firm should I choose is required some R&D. Any idea?
Shorts will attack again and BRCD may see much lower prices.